Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 2.08x is 47% below its estimated 1-year average of 3.91x, near the low end of its estimated 1-year range (1.96x–5.05x).
As of 2026-10-06T18:30:58.508Z.
Calculation as of: 2026-10-06T18:30:58.508Z.
Quote observation: 2026-10-06T18:30:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e5dd7cae71be814523bfc9444594aa14e5919ebae0d9bfc7936539f469f7652
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
2.08x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.40x
median of 549 covered companies
CURRENT VS SECTOR MEDIAN
-52.73%
vs the sector median at left
Market Cap
$11.06M
EV/Sales Ratio
6.21x
TTM Avg
63.85x
3Y Avg
37.14x
5Y Avg
37.14x
Market Cap
$11.00M
EV/Sales Ratio
7914.10x
TTM Avg
8299.41x
3Y Avg
8299.41x
5Y Avg
8299.41x
Market Cap
$11.12M
EV/Sales Ratio
N/A
TTM Avg
2.30x
3Y Avg
2.30x
5Y Avg
5910.26x
Market Cap
$11.16M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.28M
EV/Sales Ratio
N/A
TTM Avg
95.17x
3Y Avg
42.02x
5Y Avg
108.43x
Market Cap
$10.59M
EV/Sales Ratio
442.77x
TTM Avg
943.18x
3Y Avg
346.01x
5Y Avg
219.00x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerenome, Inc. (CNSY) | $11.05M | 2.08x | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.06M | 6.21x | 63.85x | 37.14x | 37.14x |
| BioVie Inc. (BIVI)vs › | $11.01M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.00M | 7914.10x | 8299.41x | 8299.41x | 8299.41x |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | N/A | 2.30x | 2.30x | 5910.26x |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.16M | N/A | N/A | N/A | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.28M | N/A | 95.17x | 42.02x | 108.43x |
| Pluri Inc. (PLUR)vs › | $10.59M | 41.32x | 47.52x | 96.27x | 132.69x |
| Senti Biosciences, Inc. (SNTI)vs › | $10.59M | 442.77x | 943.18x | 346.01x | 219.00x |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.53M | N/A | 90.97x | 348.95x | 254.75x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-05 | 1.96x |
| 2026-10-02 | 2.03x |
| 2026-10-01 | 2.32x |
| 2026-09-30 | 2.46x |
| 2026-09-29 | 2.44x |
| 2026-09-28 | 2.70x |
| 2026-09-25 | 2.65x |
| 2026-09-24 | 2.46x |
| 2026-09-23 | 2.59x |
| 2026-09-22 | 2.72x |
| 2026-09-21 | 2.51x |
| 2026-09-18 | 2.72x |
| 2026-09-17 | 2.72x |
| 2026-09-16 | 2.73x |
| 2026-09-15 | 2.86x |
| 2026-09-14 | 2.94x |
| 2026-09-11 | 3.20x |
| 2026-09-10 | 3.30x |
| 2026-09-09 | 3.46x |
| 2026-09-08 | 3.80x |
| 2026-09-04 | 3.90x |
| 2026-09-03 | 4.25x |
| 2026-09-02 | 4.19x |
| 2026-09-01 | 3.81x |
| 2026-08-31 | 3.99x |
| 2026-08-28 | 4.36x |
| 2026-08-27 | 4.44x |
| 2026-08-26 | 4.31x |
| 2026-08-25 | 4.43x |
| 2026-08-24 | 4.22x |
| 2026-08-21 | 4.39x |
| 2026-08-20 | 4.28x |
| 2026-08-19 | 4.59x |
| 2026-08-18 | 4.41x |
| 2026-08-17 | 4.60x |
| 2026-08-14 | 4.28x |
| 2026-08-13 | 4.30x |
| 2026-08-12 | 4.30x |
| 2026-08-11 | 4.47x |
| 2026-08-10 | 4.48x |
| 2026-08-07 | 4.47x |
| 2026-08-06 | 4.51x |
| 2026-08-05 | 4.57x |
| 2026-08-04 | 4.64x |
| 2026-08-03 | 4.07x |
| 2026-08-02 | 4.46x |
| 2026-07-31 | 4.52x |
| 2026-07-30 | 4.24x |
| 2026-07-29 | 4.21x |
| 2026-07-28 | 4.38x |
| 2026-07-27 | 4.34x |
| 2026-07-24 | 4.47x |
| 2026-07-23 | 4.40x |
| 2026-07-22 | 4.46x |
| 2026-07-21 | 4.58x |
| 2026-07-20 | 4.47x |
| 2026-07-17 | 4.35x |
| 2026-07-16 | 4.56x |
| 2026-07-15 | 4.79x |
| 2026-07-14 | 5.05x |
| 2026-07-13 | 4.90x |
| 2026-07-10 | 4.69x |
| 2026-07-09 | 4.69x |
| 2026-07-08 | 4.46x |
| 2026-07-07 | 4.58x |
| 2026-07-06 | 4.75x |
